Burn-wound infection
Burn wounds are a leading portal for invasive, hard-to-treat infection: the destroyed skin barrier, devitalized tissue, and prolonged ICU stays favor colonization by Pseudomonas aeruginosa and Acinetobacter baumannii, two of the WHO's highest-priority multidrug-resistant pathogens, which readily form biofilms on eschar and wound beds and drive sepsis and graft failure. Rising carbapenem and colistin resistance in these organisms has narrowed antibiotic options, making burn-wound infection one of the most cited indications for bacteriophage therapy. Phages are attractive here because they are naturally lytic against specific bacteria, self-amplify at the site of infection, penetrate biofilm, and can be applied topically to an accessible wound surface while sparing commensal flora. The wound's accessibility also makes it ideal for compassionate-use cocktails and for combining phages with the antibiotics and surgical debridement already standard in burn care.
How phages act here
Mechanism
Lytic phages bind strain-specific surface receptors on P. aeruginosa and A. baumannii (LPS, type IV pili, and in A. baumannii the capsular polysaccharide), inject their genome, hijack the host, and lyse the cell, so cocktails are deliberately assembled to cover multiple receptor types and broaden host range against heterogeneous burn isolates. Many therapeutic phages and engineered phage-derived enzymes (depolymerases, endolysins) degrade the exopolysaccharide matrix and capsule, stripping biofilm and exposing bacteria to immune cells and antibiotics — a key advantage on eschar where biofilm blunts antibiotics. Phage-antibiotic synergy (PAS) is repeatedly observed: sub-lethal antibiotics can boost phage replication, and phage pressure can re-sensitize resistant bacteria, because escape mutants that lose the phage receptor (e.g., capsule or efflux/porin changes) often pay a fitness cost that restores antibiotic susceptibility. Engineered and CRISPR-armed phages are in development to expand host range and re-sensitize MDR strains, but burn-wound clinical practice to date relies chiefly on natural lytic cocktails, often personalized and paired with antibiotics.
Where it stands
Current evidence
Evidence spans a landmark randomized trial, landmark personalized case reports, and active preclinical burn models, but no phage product is yet licensed for this indication. The PhagoBurn trial (NCT02116010; Jault et al., Lancet Infect Dis 2019) was the first randomized, controlled, double-blind phase 1/2 study of a 12-phage anti-P. aeruginosa cocktail (PP1131) applied topically to infected burn wounds in France/Belgium/Switzerland; it is best understood as a cautionary proof-of-concept, because a manufacturing defect dropped the delivered titer roughly 10,000-fold (about 10^2 instead of 10^6 PFU/mL), so the phage arm reduced bacterial burden more slowly than silver sulfadiazine and the trial was stopped early — underscoring that dosing and GMP manufacturing, not phage biology, were limiting. For A. baumannii, the field-defining clinical evidence is the 2016 UC San Diego personalized IV/percutaneous phage cocktail that rescued a patient with disseminated MDR A. baumannii (Schooley et al., AAC 2017), which launched the IPATH center and dozens of subsequent compassionate-use cases including burn/wound and ventilator-associated infections. Preclinical burn-specific work continues, e.g., a 2025 mouse burn-skin model showing a lytic phage plus an engineered capsule depolymerase reduced K9-type A. baumannii burden (Borzilov et al., Viruses 2025). As of 2026 the consensus is that topical/local phage cocktails for burn P. aeruginosa and A. baumannii are promising and safe under expanded-access/compassionate use, with adequately dosed, well-manufactured randomized trials still the key missing piece.
Evidence confidence: medium
The data
Key studies & trials
- Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19(1):35-45. ↗
- Schooley RT, Biswas B, Gill JJ, et al. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother. 2017;61(10):e00954-17. ↗
- Borzilov AI, Volozhantsev NV, Korobova OV, et al. Bacteriophage and Phage-Encoded Depolymerase Exhibit Antibacterial Activity Against K9-Type Acinetobacter baumannii in Mouse Sepsis and Burn Skin Infection Models. Viruses. 2025;17(1):70. ↗
- PhagoBurn: Evaluation of Phage Therapy for the Treatment of Escherichia coli and Pseudomonas aeruginosa Wound Infections in Burned Patients (registered trial record). ClinicalTrials.gov identifier NCT02116010; EudraCT 2014-000714-65. ↗
Who is working on it
Programs & centers
The possibility
Because a burn wound is a visible, accessible surface, it is arguably the ideal proving ground for the next generation of phage medicine: personalized cocktails matched to a patient's isolate within days, delivered in hydrogels or smart dressings that release phage and antibiotic on demand as biofilm is sensed. Engineered and depolymerase-armed phages could routinely peel biofilm off eschar and re-sensitize pan-resistant P. aeruginosa and A. baumannii so that older antibiotics work again, turning today's untreatable burn infections into manageable ones. If a properly dosed, GMP-manufactured trial finally lands the efficacy signal that PhagoBurn's diluted product missed, phage-augmented burn care could become a standard adjunct in burn ICUs worldwide within the decade.